Access cutting-edge parkinson disease treatment through this early phase 1 clinical trial at a research site in Minneapolis. Study-provided care at no cost to qualified participants.
Quick Self-Assessment
See if you qualify for this Minneapolis location
Preparing your pre-screening questions…
Access parkinson disease specialists at no cost
This study follows strict safety protocols and ethical guidelines
All study-related parkinson disease treatment provided free
Check if you qualify for this parkinson disease clinical trial in Minneapolis, MN
No-Cost Study Care
Local to Minneapolis
Convenient for MN residents
Cutting-Edge Treatment
Access to innovative therapies
Expert Medical Care
Close monitoring by specialists
Possible Compensation*
For time and travel
*Compensation varies by study. Confirm details with coordinator.
Sixty patients will be enrolled in this study who are treated for Parkinson's disease (PD) with bilateral deep brain stimulation of subthalamic nucleus (STN) or globus pallidus (GP), who have a pre- operative 7 Tesla MRI including diffusion tensor imaging for tractography and a postoperative head CT for electrode localization, and in whom at least 3 months have passed since activation of their neurostimulators, for stabilization of clinical stimulator settings. Using their MRI and CT, the investigators will construct patient-specific models of electrical current spread to neuroanatomical tar- gets surrounding the electrode. Then applying nonlinear (particle swarm) optimization, patient- specific stimulator settings will be designed to maximally or minimally activate specific path- ways. In STN DBS: pedunculopallidal vs. pallidopeduncular pathways. In GP DBS: pallidopeduncular pathways at its origin in GP pars interna (GPi) vs. inhibitory afferents to GPi (from GP pars externa GPe). All stimulation falls within the the FDA-approved range for DBS for PD.
Sponsor: University of Minnesota
Yes, this clinical trial (NCT05893186) has an active research site in Minneapolis, MN that is currently enrolling participants.
Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.
Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.
Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.
If you're searching for parkinson disease treatment options in Minneapolis, MN, this clinical trial (NCT05893186) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.
Our Minneapolis research site is actively enrolling participants for this early phase 1 clinical trial. You'll receive care from experienced parkinson disease specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.
Looking for more options? Browse all parkinson disease clinical trials near you to find additional studies recruiting in your area.
See all parkinsons disease clinical trials recruiting in Minneapolis — not just this study.
Browse Parkinsons Disease Trials in Minneapolis →